SKP2 and neoplasm: In vitro, SZL-P1–41 inhibits the interaction between SKP1 and SKP2 and consequently restricts cancer cell survival in a p53-dependent manner, along with inhibited aerobic glycolysis and enhanced anti-tumor activity in vivo [230].